Effects of sitagliptin treatment on dysmetabolism, inflammation, and oxidative stress in an animal model of type 2 diabetes (ZDF rat) - Test2 - elhamkhani - TriplyDB

Effects of sitagliptin treatment on dysmetabolism, inflammation, and oxidative stress in an animal model of type 2 diabetes (ZDF rat)

Effects of sitagliptin treatment on dysmetabolism, inflammation, and oxidative stress in an animal model of type 2 diabetes (ZDF rat)

http://www.wikidata.org/entity/Q34003019

about

Dipeptidyl peptidase-4 and kidney fibrosis in diabetes Role of dipeptidyl peptidase-4 inhibitors in new-onset diabetes after transplantation Dipeptidyl-peptidase 4 inhibition: linking metabolic control to cardiovascular protection Effect of Probiotics on Glycemic Control: A Systematic Review and Meta-Analysis of Randomized, Controlled Trials A 6-week training program increased muscle antioxidant system in elderly diabetic fatty rats Pancreatic fat accumulation, fibrosis, and acinar cell injury in the Zucker diabetic fatty rat fed a chronic high-fat diet.Pleiotropic effects of the dipeptidylpeptidase-4 inhibitors on the cardiovascular system Rodent models for metabolic syndrome research.Effect of dipeptidyl peptidase 4 inhibition on arterial blood pressure is context dependent.Treatment of streptozotocin-induced diabetic rats with alogliptin: effect on vascular and neural complications.DPP-4 (CD26) inhibitor alogliptin inhibits atherosclerosis in diabetic apolipoprotein E-deficient mice.Dipeptidyl peptidase-4 inhibitor decreases abdominal aortic aneurysm formation through GLP-1-dependent monocytic activity in mice.Diabetic nephropathy amelioration by a low-dose sitagliptin in an animal model of type 2 diabetes (Zucker diabetic fatty rat).Linagliptin treatment improves cerebrovascular function and remodeling and restores reduced cerebral perfusion in Type 2 diabetes.Cardiovascular biology of the incretin system.DPP-4 inhibition improves early mortality, β cell function, and adipose tissue inflammation in db/db mice fed a diet containing sucrose and linoleic acid.Dipeptidylpeptidase inhibition is associated with improvement in blood pressure and diastolic function in insulin-resistant male Zucker obese rats Sitagliptin reduces hyperglycemia and increases satiety hormone secretion more effectively when used with a novel polysaccharide in obese Zucker rats.Sitagliptin attenuates cardiomyopathy by modulating the JAK/STAT signaling pathway in experimental diabetic rats.Protective effect of the omega-3 polyunsaturated fatty acids: Eicosapentaenoic acid/Docosahexaenoic acid 1:1 ratio on cardiovascular disease risk markers in rats.Reduced miR-200b and miR-200c expression contributes to abnormal hepatic lipid accumulation by stimulating JUN expression and activating the transcription of srebp1.Sitagliptin prevents aggravation of endocrine and exocrine pancreatic damage in the Zucker Diabetic Fatty rat - focus on amelioration of metabolic profile and tissue cytoprotective properties Sitagliptin prevents inflammation and apoptotic cell death in the kidney of type 2 diabetic animals Renal and cardiac effects of DPP4 inhibitors--from preclinical development to clinical research.Cardiovascular effects of gliptins.The emerging role of dipeptidyl peptidase-4 inhibitors in cardiovascular protection: current position and perspectives.Dipeptidyl peptidase-4 inhibitors: multitarget drugs, not only antidiabetes drugs.Dipeptidyl peptidase-4 inhibitors and their effects on the cardiovascular system.Dipeptidyl peptidase-4 inhibitors in cardioprotection: a promising therapeutic approach.Antiatherothrombotic effects of dipeptidyl peptidase inhibitors.Cardiovascular actions of GLP-1 and incretin-based pharmacotherapy.Linagliptin: from bench to bedside.Vascular protection with dipeptidyl peptidase-IV inhibitors in diabetes: experimental and clinical therapeutics.Ameliorating Effect of Gemigliptin on Renal Injury in Murine Adriamycin-Induced Nephropathy.The Place of Dipeptidyl Peptidase-4 Inhibitors in Type 2 Diabetes Therapeutics: A "Me Too" or "the Special One" Antidiabetic Class?The SGLT2 inhibitor empagliflozin improves the primary diabetic complications in ZDF rats.The incretin system ABCs in obesity and diabetes - novel therapeutic strategies for weight loss and beyond.DPP-4 inhibitors in diabetic complications: role of DPP-4 beyond glucose control.Renoprotective effects of a dipeptidyl peptidase 4 inhibitor in a mouse model of progressive renal fibrosis.Cardioprotective effects of sitagliptin against doxorubicin-induced cardiotoxicity in rats.

P2860

Q26766089-CB198EBD-C9B7-4F84-8FEE-97D2A336CE5C Q26778329-E547E306-5422-4ADA-8650-3C818701A0AE Q27011819-985F83DD-EE4E-47A2-9061-91AA522E4B2B Q28080687-ED30EDAF-CD30-4D3A-9A9C-BB45B8176BFA Q28393888-9A9B0BE4-2BA8-46D6-B6F3-71909219FB06 Q33825167-B124DB58-A94D-4BD9-86FD-D63CCCF931D0 Q34062829-65049375-DD5A-4BE1-98EC-43997C123258 Q34479248-8BEE6823-D4C7-466D-B688-EFEAB37A4934 Q34718326-235ECC50-8D13-4866-96EE-AB9B6E20DB95 Q35125198-8103918D-2CA3-4BB5-B636-0B17FA532FE5 Q35161203-44023FC4-5549-4935-B97C-332EE3191C60 Q35413944-70F138A7-0FC8-4D43-B2A5-16828531693C Q35607330-DD0FC29D-44DB-484F-8643-A2852A9F3F05 Q36064392-A58AFA0F-9203-4A82-8304-88EB6A21D27D Q36484283-BC53697B-F598-4A7F-B693-E4DC9737F46F Q36639293-AA139398-8140-46FB-AD00-C610F13C32A8 Q36946065-B75FA88F-0254-4686-8A5B-D4B3D42BD8EE Q37033531-38044A2B-ADDE-4172-8D7A-D1F1621F0B6F Q37066737-AA372A68-C00A-4845-96D6-31469DA89D40 Q37363599-4FFB441D-F299-4DBB-8ED3-FCA1A572BC94 Q37392679-2E0ECCAD-EFE7-4E01-98F1-C39D84216499 Q37720797-681DFE2B-8EBA-460A-A52D-DCB309A6BD9B Q37725539-146B3C7F-A050-477A-9C15-484B0B3C3004 Q38040596-9AA57749-09DB-4482-B666-C1D4EA0D3DD1 Q38072259-0946C497-2413-4ECC-85FB-4ACA4796B94B Q38104293-A19345C1-02BF-4B84-B3CE-2A41EC4E61D2 Q38107546-A4A19403-2AE2-46BD-856D-93281D9D01CC Q38118157-7606FB26-8DF7-4D8C-ABDB-B3C770A32E8A Q38119146-FFD8A863-85E5-4235-83F2-8740A3BDD7A4 Q38195527-898B63FE-8975-40E3-9911-6D572E6FC758 Q38199984-11751537-0FCB-4E95-B246-0F7C130B5649 Q38213703-FDD59B18-F140-4D99-B89E-AA9D3CB23EA0 Q38371242-05516673-9F71-4023-A575-5D1CE9365668 Q38404674-6470EF7E-72E5-4015-BB81-BC01A1ADF6BC Q38527885-EA76E628-CE32-4CD6-8B21-D37B95BCB0D8 Q38698841-0ABAFF34-4BEB-4A64-BA3D-D1CC4DE12AB3 Q38820260-FE4291F3-BEB7-45AB-BD11-3283451D2C3D Q38922177-04625E8C-427A-48EF-ADA5-E8A146986627 Q39001492-CD3AB8DC-D9F5-4396-8066-E76E00D1DBD0 Q39870539-439628AC-C380-4491-ABE3-5A8255DB2026

P2860

Effects of sitagliptin treatment on dysmetabolism, inflammation, and oxidative stress in an animal model of type 2 diabetes (ZDF rat)

http://www.wikidata.org/entity/Q34003019

description

2010 nî lūn-bûn

@nan

2010 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Effects of sitagliptin treatme ...... l of type 2 diabetes (ZDF rat)

@ast

Effects of sitagliptin treatme ...... l of type 2 diabetes (ZDF rat)

@en

Effects of sitagliptin treatme ...... l of type 2 diabetes (ZDF rat)

@nl

type

label

Effects of sitagliptin treatme ...... l of type 2 diabetes (ZDF rat)

@ast

Effects of sitagliptin treatme ...... l of type 2 diabetes (ZDF rat)

@en

Effects of sitagliptin treatme ...... l of type 2 diabetes (ZDF rat)

@nl

prefLabel

Effects of sitagliptin treatme ...... l of type 2 diabetes (ZDF rat)

@ast

Effects of sitagliptin treatme ...... l of type 2 diabetes (ZDF rat)

@en

Effects of sitagliptin treatme ...... l of type 2 diabetes (ZDF rat)

@nl

P1433

Q34003019-AD523AAE-9852-4623-885D-9557472D33F5

P1476

Q34003019-6D32A8DF-C7D9-4112-AAC1-307FA31E5040

P2093

Q34003019-17ABD5FF-836E-42AC-AB2B-D877CADCDB5B

Q34003019-24375424-E002-45F4-A911-60066658B253

Q34003019-4A61CF59-99A8-45DD-A53B-1978EA41E169

Q34003019-64E805A4-65AD-47B5-B802-2AE1257B158B

Q34003019-6F3267A8-3709-44EA-B561-792879D0141A

Q34003019-725A904E-81FB-4EB3-99B7-986D2249BCFE

Q34003019-8B9919AE-0594-4539-9B88-4B7CD8C87983

Q34003019-8EA92A4A-3CC6-4377-88BB-E9DDCBE097AC

Q34003019-A1D77BB5-6228-4E4A-B276-2FAE91259571

Q34003019-A6D08FB1-F67D-4BD2-8795-847D72743DB1

P2860

Q34003019-065FBE96-BC81-4D23-AAF6-A869B4B93B4B

Q34003019-107885E4-2B51-46F7-A119-7F30557C0B41

Q34003019-13616208-41B4-4745-9645-C90E29AF831B

Q34003019-16432EA7-0DD1-482C-B53E-1D999CA8016A

Q34003019-1A586C14-77E7-4E71-9953-EADB73E8DFC3

Q34003019-278BF4C7-BFD2-4ABF-AE02-9B69E2092780

Q34003019-365ED3E0-F30F-4A4B-B5AC-1386922654F5

Q34003019-3A3805B5-7E90-438E-826D-999D3FA13646

Q34003019-3A8C7D1C-F18B-4F66-9093-F3220B058A73

Q34003019-40D8C573-7B9B-4C4D-AE1E-B6C63747E300

P304

Q34003019-E00182A2-C862-4AED-BE6D-CC8C97AA9793

P31

Q34003019-783B72D9-D351-4E8C-A521-DB7B022DEBD5

P356

Q34003019-E549448F-2781-4D06-8A0E-E18C11CF7019

P478

Q34003019-76A38431-117A-4601-9D18-44D0BBC81F66

P50

Q34003019-0C6BE280-0F61-4EB9-9C74-F76472D4D406

Q34003019-9AA27878-E567-4C57-8866-41EB67246600

P577

Q34003019-8C89C262-B6D4-4CC5-9836-31F9C6DB88B5

P5875

Q34003019-CE0716A3-28E7-4BF7-A75A-91C66FD2C022

P698

Q34003019-12AA61B3-AE4D-458B-BD61-1E8C922BB922

P921

Q34003019-B323FF7F-0B3C-4080-98F3-656E717905B8

P932

Q34003019-1CCBEBCD-2E79-46F3-B2FB-7141DC145464

P356

P1433

Mediators of Inflammation

P1476

Effects of sitagliptin treatme ...... l of type 2 diabetes (ZDF rat)

@en

P2093

Andreia Melo

http://www.w3.org/2001/XMLSchema#string

Belmiro Parada

http://www.w3.org/2001/XMLSchema#string

Cristina Mega

http://www.w3.org/2001/XMLSchema#string

Edite Teixeira-de-Lemos

http://www.w3.org/2001/XMLSchema#string

Filipa Pinto

http://www.w3.org/2001/XMLSchema#string

Helena Vala

http://www.w3.org/2001/XMLSchema#string

Isabel Velada

http://www.w3.org/2001/XMLSchema#string

José Sereno

http://www.w3.org/2001/XMLSchema#string

Liliana Ferreira

http://www.w3.org/2001/XMLSchema#string

Patrícia Garrido

http://www.w3.org/2001/XMLSchema#string

P2860

Beneficial endocrine but adverse exocrine effects of sitagliptin in the human islet amyloid polypeptide transgenic rat model of type 2 diabetes: interactions with metformin

Global prevalence of diabetes: estimates for the year 2000 and projections for 2030

Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes

The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes

Disruption of adiponectin causes insulin resistance and neointimal formation

Type 2 diabetes--therapy with dipeptidyl peptidase IV inhibitors.

Type 2 diabetes mellitus: epidemiology, pathophysiology, unmet needs and therapeutical perspectives.

Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link?

Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia.

Control of energy homeostasis and insulin action by adipocyte hormones: leptin, acylation stimulating protein, and adiponectin.

P304

592760

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1155/2010/592760

http://www.w3.org/2001/XMLSchema#string

P478

2010

http://www.w3.org/2001/XMLSchema#string

P50

Frederico Teixeira

P577

2010-06-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

45283024

http://www.w3.org/2001/XMLSchema#string

P698

20652060

http://www.w3.org/2001/XMLSchema#string

P921

type-2 diabetes

P932

2905949

http://www.w3.org/2001/XMLSchema#string